i posted this on biotech board don dew, rkrw or biomaven poorgrad or some of the other very good on this board yesterday on aria cc the ceo states"We remain as optimistic as ever that there’s a strong likelihood of a positive clinical outcome".
is this usuall or do we take this as pretty good sign there getting data back and they have real good idea??????? here is the rest of it
It should be pointed out that the design of this trial shares several aspects of the phase III Succeed trial of oral Ridaforolimus in patients with metastatic, soft tissue and bone sarcomas – that is, both trials evaluate singe agent Ridaforolimus in a randomized setting against a PSS endpoint, and both trials utilize the same oral dose and schedule of Ridaforolimus. The interim results from the phase II study of Ridaforolimus in endometrial cancer therefore reinforces our confidence in a potential positive outcome to the Succeed trial.
Now let me turn the call back over to Harvey.
Dr. Harvey Berger
Thank you very much, Tim. Before we open the call to questions I’d like to provide a short update on the Succeed trial. Merck has recently communicated to us that the full number of PFS events in the study has been reached. The final data collection is now underway and being performed by our colleagues at Merck. As such, we expect top line final PFS results from the Succeed trial to be announced in the Q1 of 2011, and that we will communicate these findings along with our partner, Merck. We remain as optimistic as ever that there’s a strong likelihood of a positive clinical outcome and we look forward to early next year when a report of the top line results is anticipated.
h board
